Literature DB >> 12716733

Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.

Carla J Greenbaum1, Leonard C Harrison.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12716733     DOI： 10.2337/diabetes.52.5.1059

Source DB:  PubMed          Journal:  Diabetes        ISSN： 0012-1797            Impact factor:   9.461


× No keyword cloud information.
  28 in total

1.  Trials of immunotherapy to preserve beta-cell function of prediabetic and new-onset patient trials.

Authors:  George S Eisenbarth
Journal:  Curr Diab Rep       Date:  2004-04       Impact factor: 4.810

2.  Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetes.

Authors:  Carla J Greenbaum
Journal:  Curr Diab Rep       Date:  2006-04       Impact factor: 4.810

3.  Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.

Authors:  Bart O Roep; Nanette Solvason; Peter A Gottlieb; Joana R F Abreu; Leonard C Harrison; George S Eisenbarth; Liping Yu; Michael Leviten; William A Hagopian; John B Buse; Matthias von Herrath; Joanne Quan; Robert S King; William H Robinson; Paul J Utz; Hideki Garren; Lawrence Steinman
Journal:  Sci Transl Med       Date:  2013-06-26       Impact factor: 17.956

4.  Capturing residual beta cell function in type 1 diabetes.

Authors:  Flemming Pociot
Journal:  Diabetologia       Date:  2018-11-03       Impact factor: 10.122

5.  Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.

Authors:  J B Matthews; T P Staeva; P L Bernstein; M Peakman; M von Herrath
Journal:  Clin Exp Immunol       Date:  2010-05       Impact factor: 4.330

6.  Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial.

Authors:  I Conget; E Aguilera; S Pellitero; S Näf; K Bendtzen; R Casamitjana; R Gomis; F Nicoletti
Journal:  Diabetologia       Date:  2005-07-02       Impact factor: 10.122

7.  Parenteral insulin suppresses T cell proliferation to islet antigens.

Authors:  Carla J Greenbaum; Marli McCulloch-Olson; Harvey K Chiu; Jerry P Palmer; Barbara Brooks-Worrell
Journal:  Pediatr Diabetes       Date:  2011-05       Impact factor: 4.866

8.  Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.

Authors:  Marian Rewers; Peter Gottlieb
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

9.  Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.

Authors:  Maria Anita Radtke; Ingrid Nermoen; Magnus Kollind; Svein Skeie; Jan Inge Sørheim; Johan Svartberg; Ingrid Hals; Torolf Moen; Gry Høst Dørflinger; Valdemar Grill
Journal:  Diabetes Care       Date:  2009-12-22       Impact factor: 19.112

10.  Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.

Authors:  Frantisek Saudek; Tereza Havrdova; Petr Boucek; Ludmila Karasova; Peter Novota; Jelena Skibova
Journal:  Rev Diabet Stud       Date:  2004-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.